Ciprofloxacin | Solubility of Things

Identification

Molecular formula

C₁₇H₁₈FN₃O₃

CAS number

85721-33-1

IUPAC name

1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid

State

At room temperature, ciprofloxacin is in a solid state. It is commonly available in the form of tablets, a solution for intravenous infusion, and optical preparations. It is stored in a dry and cool environment to maintain its stability and efficacy.

Melting point (Celsius)

318.00

Melting point (Kelvin)

591.15

Boiling point (Celsius)

542.40

Boiling point (Kelvin)

815.55

General information

Molecular weight

331.35g/mol

Molar mass

331.3450g/mol

Density

1.5000g/cm³

Appearence

Ciprofloxacin typically appears as a faint to light yellow crystalline powder. It may also be described as colorless or white, depending on purity and specific conditions. Due to its crystal structure, it can has a glistening appearance under light.

Comment on solubility

Solubility of 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid

The solubility of 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid, with the chemical formula C₁₇H₁₈FN₃O₃, is an intriguing topic due to its complex structure. Factors affecting its solubility include:

Polarity: The presence of both a carboxylic acid group and a piperazine moiety implies varying degrees of polarity, which can influence solubility in polar solvents like water.
Hydrogen bonding: This compound can potentially engage in hydrogen bonding due to the -COOH group (carboxylic acid), enhancing solubility in aqueous solutions.
Functional groups: The fluoro group may enhance the compound's interaction with solvents, further complicating the solubility profile.

However, it is important to note that while the theoretical aspects suggest moderate solubility characteristics, actual solubility may vary significantly due to:

Environmental conditions: pH, temperature, and solvent composition can all affect solubility.
Concentration effects: Increased concentration can lead to precipitation, indicating a limit on solubility.

In practical applications, solubility testing in various solvents will provide a clearer understanding of this compound's behavior. Thus, empirical evidence is crucial for any definitive claims about solubility.

Interesting facts

Interesting Facts about 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic Acid

1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid is a fascinating compound that has drawn significant interest in the field of medicinal chemistry. Here are some compelling aspects of this intriguing chemical:

Pharmacological Applications: This compound is known for its role in developing antimalarial and antibacterial agents. Researchers are actively exploring its potential as a therapeutic agent to combat resistant strains of pathogens.
Structural Characteristics: The presence of the quinoline ring, known for its diverse biological activity, is a significant feature. This bicyclic structure is a key element in many pharmacologically relevant compounds.
Fluorine Atom: The inclusion of a fluorine atom at position 6 often enhances the lipophilicity of the compound, potentially improving its bioavailability, a crucial factor in drug design.
Piperazine Moiety: The piperazine ring is often utilized in drug development due to its ability to interact with various biological targets, enhancing the compound's efficacy.
Research Interest: The compound has gained attention in recent studies aimed at exploring its mechanisms of action and optimizing its therapeutic profile. As researchers delve deeper, we might uncover novel applications that extend beyond its current uses.

Overall, 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid represents a significant intersection of structure and function, making it a valuable subject of study in the ongoing quest for effective pharmaceutical agents.

Synonyms

norfloxacin

70458-96-7

Noroxin

Norfloxacine

Chibroxin

Baccidal

Sebercim

Norfloxacino

MK-366

Norfloxacinum

Barazan

Fulgram

AM-715

NFLX

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid

1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

Lexinor

Zoroxin

AM 715

MFCD00079532

Norfloxacine [INN-French]

Norfloxacinum [INN-Latin]

Norfloxacino [INN-Spanish]

1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid

3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-

CCRIS 6302

CHEBI:100246

EINECS 274-614-4

UNII-N0F8P22L1P

1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure

NSC-757250

BRN 0567897

MK-0366

N0F8P22L1P

DTXSID7037680

1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid

HSDB 8029

CHEMBL9

1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid

MLS000069650

DTXCID5017680

3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-

NSC 757250

Norfloxacin [USAN:USP:INN:BAN:JAN]

NCGC00016916-01

NCGC00016916-09

SMR000058200

Norfloxacin 100 microg/mL in Acetonitrile

CAS-70458-96-7

1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid

Norfloxacine (INN-French)

Norfloxacinum (INN-Latin)

Norfloxacino (INN-Spanish)

NORFLOXACIN (MART.)

NORFLOXACIN [MART.]

C16H18FN3O3

NORFLOXACIN (USP-RS)

NORFLOXACIN [USP-RS]

NORFLOXACIN (EP MONOGRAPH)

NORFLOXACIN (USP IMPURITY)

NORFLOXACIN [EP MONOGRAPH]

NORFLOXACIN [USP IMPURITY]

Norflo

MK 0366

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid

Norfloxacin (USAN:USP:INN:BAN:JAN)

Noroxin (TN)

1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid

SR-01000000222

norfloxacina

Chibroxine

Chibroxol

Gonorcin

Nolicin

Noracin

Noraxin

Norocin

Noroxine

Norxacin

Uroxacin

Utinor

Noflo

Norfloxacine,(S)

Prestwick_633

Norfloxacin protomer I

Norfloxacin (Norxacin)

Norfloxacin (Standard)

Norfloxacin protomer II

Spectrum_001017

NORFLOXACIN [MI]

Opera_ID_1423

Prestwick0_000221

Prestwick1_000221

Prestwick2_000221

Prestwick3_000221

Spectrum2_001017

Spectrum3_000524

Spectrum4_000453

Spectrum5_001154

NORFLOXACIN [INN]

NORFLOXACIN [JAN]

PEFLOXACINE_met009

NORFLOXACIN [USAN]

Epitope ID:119068

NORFLOXACIN [VANDF]

SCHEMBL3473

Oprea1_375152

BSPBio_000261

BSPBio_002107

KBioGR_000866

KBioSS_001497

NORFLOXACIN [WHO-DD]

MLS006011446

BIDD:GT0725

DivK1c_000084

SPECTRUM1500440

SPBio_001173

SPBio_002182

BPBio1_000289

Norfloxacin (JP18/USP/INN)

BCBcMAP01_000218

GTPL12408

HMS500E06

HY-B0132R

KBio1_000084

KBio2_001497

KBio2_004065

KBio2_006633

KBio3_001607

J01MA06

NORFLOXACIN [ORANGE BOOK]

S01AE02

NINDS_000084

Norfloxacin for system suitability

GLXC-20579

HMS1568N03

HMS1920B16

HMS2090F03

HMS2091J16

HMS2095N03

HMS2235G03

HMS3712N03

Norfloxacin for peak identification

Pharmakon1600-01500440

ALBB-015911

BCP27734

HY-B0132

RKL10074

Tox21_110682

Tox21_113441

1-ethyl-6-fluoro-4-oxo-7-piperazinylhydroquinoline-3-carboxylic acid

BBL005569

BDBM50045000

CCG-40235

NSC757250

s1509

STK177250

AKOS000417391

Tox21_110682_1

AC-6855

AN26450

BCP9000993

CS-1906

DB01059

KS-5007

1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxylic Acid

IDI1_000084

SMP1_000216

NCGC00016916-02

NCGC00016916-03

NCGC00016916-04

NCGC00016916-05

NCGC00016916-06

NCGC00016916-07

NCGC00016916-08

NCGC00016916-11

NCGC00016916-12

NCGC00021725-03

NCGC00021725-04

SY051390

SBI-0051464.P002

N0817

NS00000224

EN300-06467

C06687

D00210

AB00052059-18

AB00052059-19

AB00052059_20

AB00052059_21

Norfloxacin, analytical standard, >=98% (TLC)

Norfloxacin, VETRANAL(TM), analytical standard

Q417897

SR-01000000222-2

SR-01000000222-3

BRD-K11196887-001-05-5

BRD-K11196887-001-15-4

BRD-K11196887-001-20-4

BRD-K11196887-001-21-2

BRD-K11196887-001-22-0

Z56926638

Norfloxacin, British Pharmacopoeia (BP) Reference Standard

Norfloxacin, European Pharmacopoeia (EP) Reference Standard

1-Ethyl-3-carboxy-6-fluoro-7-(piperazinyl-1)-quinolin-4(1H)-one

Norfloxacin, United States Pharmacopeia (USP) Reference Standard

1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaure

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-3-quinolinecarboxylic acid

Norfloxacin, Pharmaceutical Secondary Standard; Certified Reference Material

(NFLX)1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid

1-ethyl-1,4-dihydro-6-fluoro-4-oxo-7-(1-piperazinyl)quinoline-3-carboxylic acid

1-ethyl-4-oxo-6-fluoro-7-(piperazinyl)-1,4-dihydro-quinoline-3-carboxylic acid

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylicAcid

1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)quinoline-3-carboxylic acid

1-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid

1-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-carboxylic acid

1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid #

1-ethyl-6-fluoro-7-(1-piperazinyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

1-ethyl-6-fluoro-7-(1-piperazinyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

7-(1-Piperazinyl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard

Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

(norfloxacin)1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid;Baccidal;Barazan

1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4,4a,8a-tetrahydro-quinoline-3-carboxylic acid (norfloxacin)

1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid (Norfloxacin)

1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid(1-norfloxacin)

1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid(Norfloxacin)

274-614-4